Multicenter phase 3 trial of niraparib maintenance therapy among patients with newly diagnosed advanced ovarian cancer

The efficacy of niraparib maintenance therapy warrants further investigation in a broad population of patients with newly diagnosed advanced ovarian cancer, including patients without postoperative residual disease. The multicenter phase 3 PRIME trial in China included 384 patients with response to first-line platinum-based chemotherapy after debulking surgery, including patients with R0 resection. Patients were randomized to niraparib maintenance therapy with an individualized starting dose or placebo. Niraparib maintenance therapy reduced the risk of disease progression or death by 55%. Risk reduction was seen regardless of postoperative residual disease or biomarker status. The authors conclude that these results support niraparib maintenance therapy in a broad patient population with advanced ovarian cancer (visual abstract).